Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED  

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Veterinary Medicine API  > Sparfloxacin CAS 110871-86-8 at4140 ci978 Clorsulon Vetranal

Sparfloxacin CAS 110871-86-8 at4140 ci978 Clorsulon Vetranal 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: As per request of clients
CAS: 110871-86-8
Molecular weight: 359.3947
Melting point: 265℃
Flash point: 302.1°C
Vapour Pressur: 4.2E-14mmHg at 25°C
Production Capacity: 100Ton/year
Delivery Date: within 7 days
Molecular formula: C19H22FN3O3
Density: 1.347g/cm3
Boiling point: 575.9°C at 760 mmHg
Refractive index: 1.611

Sparfloxacin achieves a high degree of penetration into most tissues, except for the central nervous system.

Sparfloxacin (CAS 110871-86-8)


Molecular FormulaC19H22FN3O3
Molecular Weight359.3947
Density1.347g/cm3
Melting point265℃
Boiling point575.9°C at 760 mmHg
Refractive index1.611
Flash point302.1°C
Vapour Pressur4.2E-14mmHg at 25°C

Sparfloxacin (spar FLOX a sin), trade names Spacin in Bangladesh, Zagam and Zagam Respipac, is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile. Zagam is no longer available in the United States.


Pharmacological properties

Sparfloxacin is about 37-45% bound to proteins in the blood.


Sparfloxacin achieves a high degree of penetration into most tissues, except for the central nervous system.

Following a single 400 mg oral dose of sparfloxacin, the mean peak concentration in cantharides-induced inflammatory fluid is 1.3 lA-g per ml after a mean duration of 5 h post-dose. Thus(overall sparfloxacin penetration into inflammatory fluid is 117% and the mean elimination half-life from this fluid is 19.7 h.

Skin penetration of sparfloxacin is good with skin:plasma ratios of 1.00 at 4 h (time of peak plasma concentration) and 1.39 at 5 h. Following single oral doses of 100 or 200 mg, concentrations in skin of 0.56 and 0.82-1.31 lA-g per g, respectively, can be expected. Sparfloxacin achieves excellent penetration into human polymorphonuclear leukocytes in vitro.

Sparfloxacin achieves high concentrations in respiratory and sinus tissues. Following an oral loading dose of 400 mg followed by 200 mg daily, mean concentrations of sparfloxacin (2.5 to 5 h after dosing) in bronchial mucosa, epithelial lining fluid and alveolar macrophages are 4.4 µg/g, 15.0 µg/ml and 53.7 µg/g, respectively. The mean sparfloxacin concentration in maxillary sinus mucosa, 2-5 h after a single 400 mg dose, is 5.8 µg/g.

Shimada et al. ( 1993) has summarized many of the studies published in Japanese regarding the tissue distribution of sparfloxacin. (high concentrations are achieved in sputum, pleural fluid, skin, lung, prostate, gynecological tissues, breast milk and otolaryngological tissues. *Salivary concentrations are 66-70% of plasma levels, while CSF penetration appears to be somewhat limited with CSF:plasma concentration ratios of only 0.25-0.35.


Sparfloxacin achieves concentrations in bile and gallbladder of 7.1- to 83-fold the concurrent serum levels.

In rabbits, sparfloxacin achieves very good penetration into the ocular vitreous (54%), cornea (76%) and lens (36%).


Medical uses

The compound is indicated for treating community-acquired lower respiratory tract infections (acute sinusitis, exacerbations of chronic bronchitis caused by susceptible bacteria, community-acquired pneumonia).


Adverse drug reactions

See also: Quinolone § Adverse effects

In a review of 2081 adult patients participating in a Phase III clinical trial of sparfloxacin in community-acquired, lower respiratory tract infections, sparfloxacin (200- or 400 mg loading dose then 100 or 200 mg daily; i.e. 200/100 mg and 400/200 mg) had a similar incidence of adverse events as the comparator agents (Rubinstein, 1996). The overall rates of drug-related adverse reactions for sparfloxacin 400/200 mg versus comparators and 200/100 mg versus the comparator (amoxycillin/clavulanic acid) were 13.7 versus 17.7%, and 9.5 versus 13.2%, respectively. However, many of these reported reactions were very minor; discontinua- tion of the antibacterial agent because of drug-related adverse reactions occurred in 1.6 versus 1.6%, and 1) versus 1.1%, respectively. Adverse reactions affecting the nervous system were reported in 5.7% of the sparfloxacin group, with insomnia and other sleep disorders the most common events.

Phototoxicity was noted in 2.0% of sparfloxacin recipients, with the average delay in onset being 6.3 :t 4.5 days (range 1–14 days) after commencing sparfloxacin. Mostly this consisted of erythema on the face and hands which lasted an average of 6.4 :t 4.2 days. The incidence of phototoxicity associated with sparfloxacin appears to be higher than that observed with ciprofloxacin and ofloxacin but less than that reported for fleroxacin, pefloxacin, enoxacin and nalidixic acid.

Most importantly, features of the hemolytic-uremic syndrome such as that associated with temafloxacin have not been reported


Mechanism of action

Sparfloxacin, like other quinolones and fluoroquinolones, are bactericidal medicine, actively killing bacteria. Quinolones inhibit the bacterial DNA gyrase or the topoisomerase IV enzyme, thereby inhibiting DNA replication and transcription. Quinolones can enter cells easily and therefore are often used to treat intracellular pathogens such as Legionella pneumophila and Mycoplasma pneumoniae. For many gram-negative bacteria DNA gyrase is the target, whereas topoisomerase IV is the target for many gram-positive bacteria. Eukaryotic cells do not contain DNA gyrase or topoisomerase IV.


Sparfloxacin CAS 110871-86-8 at4140 ci978 Clorsulon Vetranal

Appearance: white powder

Sparfloxacin CAS 110871-86-8 at4140 ci978 Clorsulon Vetranal

Package: 25KG Drum or As per request of clients

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: